Eczema
Recent clinical, regulatory, research and industry developments relating to this disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q4 2027.
- 6 industry developments reported.
- Q4 2027A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
- Q2 2028A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
- Q2 2028Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis
- Q1 2032A Phase 3, Multicenter, Long-Term, Open Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic Dermatitis
Clinical MilestonesView all 13Hide
- 2026-05-27An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic DermatitisResults posted
- 2025-12-23A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects With Moderate to Severe Atopic DermatitisResults posted
- 2026-07-08A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisResults expected Q2 2028
- 2026-07-07Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult and Adolescents With Mild to Moderate Atopic DermatitisResults expected Q2 2028
- 2026-04-07A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Adolescents With Severe Atopic DermatitisResults expected Q4 2027
- 2026-04-07A Phase 3, Multicenter, Long-Term, Open Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic DermatitisResults expected Q1 2032
- 2026-04-23A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic DermatitisCompleted
- 2026-01-12A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate LNK01001 in Adults Subjects With Moderate to Severe Atopic Dermatitis.Completed
- 2025-12-23A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic DermatitisCompleted
- 2025-11-25A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)Completed
- 2025-09-12A Phase 3 Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Twice-Daily Applications of Delgocitinib Cream 20 mg/g in Chinese Adults and Adolescents (12-17 Years of Age) With Moderate to Severe Chronic Hand EczemaCompleted
- 2026-07-08A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Upadacitinib on Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis (SLEEP UP)Withdrawn
- 2026-01-13A Single-Center, Open-Label Study to Evaluate Tralokinumab in Atopic Dermatitis Subjects Who Experienced Inadequate Response on DupilumabTerminated
Industry & MarketView all 6Hide
- 2026-06-26'There's room for multiple winners': Talawar heads to Nasdaq via SPAC deal to bankroll eczema assetPartnership · Fierce Biotech
- 2026-04-07Sanofi bispecific sails through asthma, sinusitis trials, but disappoints in eczemaTrial news · Endpoints News
- 2026-06-29STAT+: Talawar bets bispecific approach can shake up eczema marketIndustry · STAT News
- 2026-07-24Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyoutRegulatory news · Fierce Biotech
- 2026-04-07Sanofi’s bispecific scores double respiratory phase 2 wins, but flunks eczema studyTrial news · Fierce Biotech
- 2026-07-24IndustrySanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyoutRegulatory news · Fierce Biotech
- 2026-07-08ClinicalA Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisResults expected Q2 2028
- 2026-07-08ClinicalA Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Upadacitinib on Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis (SLEEP UP)Withdrawn
- 2026-07-07ClinicalPhase III Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult and Adolescents With Mild to Moderate Atopic DermatitisResults expected Q2 2028
- 2026-06-29IndustrySTAT+: Talawar bets bispecific approach can shake up eczema marketIndustry · STAT News
- 2026-06-26Industry'There's room for multiple winners': Talawar heads to Nasdaq via SPAC deal to bankroll eczema assetPartnership · Fierce Biotech
- 2026-06-22IndustryAbbVie inks $10.9B Apogee buyout to bag hotly tipped eczema prospectIndustry · Fierce Biotech
- 2026-05-27ClinicalAn Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic DermatitisResults posted
- 2026-04-23ClinicalA 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic DermatitisCompleted
- 2026-04-07IndustrySanofi bispecific sails through asthma, sinusitis trials, but disappoints in eczemaTrial news · Endpoints News
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Anzupgo is indicated for the treatment of moderate to severe chronic hand eczema (CHE) (2024)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes6
- Dermatitis, Atopic2
- Eczema2
- Cytokines1
- Health Care Costs1
- Immune Checkpoint Inhibitors1
- Quality of Life1
Leading journals5
- Clinical cancer research : an official journal of the American Association for Cancer Research1
- Journal of the European Academy of Dermatology and Venereology : JEADV1
- Lancet (London, England)1
- The British journal of dermatology1
- The Journal of investigative dermatology1
Leading researchers8
- Wollenberg A3
- Cork MJ2
- Simpson EL2
- Thyssen JP2
- Aschoff R1
- Bang A1
- Bang B1
- Barbarot S1
Affiliations (unnormalised)6
- Herlev-Gentofte Hospital2
- Ludwig Maximilian University of Munich2
- Oregon Health & Science University2
- University of Sheffield2
- Aarhus University Hospital1
- Alpert Medical School of Brown University1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Eczema is a dermatitis marked by a spongiotic tissue reaction pattern. It occurs as a reaction to many endogenous and exogenous agents. The supplied grounding does not further distinguish subtypes beyond atopic dermatitis in the review abstract.
It is described as a reaction to many endogenous and exogenous agents. The grounding does not specify particular causes or aetiologies beyond this broad reactive framework.
The defining biological pattern is spongiotic dermatitis, indicating a spongiotic tissue reaction pattern. No additional mechanistic details are provided in the grounding.
The grounding does not identify specific risk factors for eczema. The review abstract only notes that atopic dermatitis can affect quality of life, family life, occupation, and economic burden, which are impacts rather than risk factors.
The supplied grounding does not describe standard treatment or drug classes for eczema. It only addresses the burden of atopic dermatitis and does not provide therapeutic guidance.
AI-generated summary grounded in MeSH and 1 peer-reviewed source. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A dermatitis characterized by a spongiotic tissue reaction pattern occurring as a reaction to many endogenous and exogenous agents.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.